KRYS - Krystal Biotech, Inc.
| Previous Close | 10.21 |
| Open | 10.32 |
| Bid | 9.82 x 2500 |
| Ask | 11.70 x 300 |
| Day's Range | 10.00 - 10.49 |
| 52 Week Range | 8.03 - 12.00 |
| Volume | 8,193 |
| Avg. Volume | 11,812 |
| Market Cap | 104.103M |
| Beta | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.48 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.00 |
- GlobeNewswire•3 days ago
Krystal Biotech’s KB103 Receives Orphan Medicinal Product Designation in Europe for Dystrophic Epidermolysis Bullosa
KB103 represents the first investigational HSV-1 based gene therapy for the severe skin disorder dystrophic epidermolysis bullosa to receive this designation. KB103 previously received Orphan Drug Designation ...
- GlobeNewswire•4 days ago
Krystal Biotech Presents Their Skin TARgeted Delivery Platform at the World Orphan Drug Congress USA
Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing “off-the-shelf” treatments for rare dermatological diseases, today announces a presentation on the Company’s proprietary technology, the Skin TARgeted Delivery Platform, or the STAR-D platform. The presentation will take place at the annual World Orphan Drug Congress USA, being held in Oxon Hill, Maryland, April 25-27, 2018.
- GlobeNewswire•26 days ago
Krystal Submits Investigational New Drug (IND) Application for KB103, Topical Gene Therapy Candidate for Dystrophic Epidermolysis Bullosa
KB103 is an internally generated modified HSV-1 based gene therapy candidate engineered with a COL7A1 gene construct to treat Dystrophic Epidermolysis Bullosa. Therapeutic candidate formulated into a topical ...
- GlobeNewswire•last month
Krystal Biotech Reports 2017 Financial Results and Business Progress
IND for KB103 to treat Dystrophic Epidermolysis Bullosa to be filed in March 2018. IND for KB105 to treat Lamellar Ichthyosis to be filed in Q4 2018. Company was granted composition of matter and method ...
- GlobeNewswire•2 months ago
Krystal Biotech, Inc. to Present at the 30th Annual ROTH Conference
PITTSBURGH, March 05, 2018-- Krystal Biotech, Inc., a gene therapy company advancing“ off-the-shelf,” treatments for dermatological diseases, today announced that Krish Krishnan, Chief Executive Officer, ...
- Simply Wall St.•6 months ago
Is Krystal Biotech Inc (KRYS) Still A Cheap Healthcare Stock?
Krystal Biotech Inc (NASDAQ:KRYS), a USD$114.55M small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence ofRead More...
- GuruFocus.com•7 months ago
Krystal Biotech Inc (KRYS) President and CEO Krish S Krishnan Bought $1,000,000 of Shares
President and CEO of Krystal Biotech Inc (NASDAQ:KRYS) Krish S Krishnan bought 100,000 shares of KRYS on 09/22/2017 at an average price of $10 a share.
- 24/7 Wall St.•7 months ago
IPO News This Week: Roku, PQ Group Lead 7 Offerings Due Out
Seven IPOs are scheduled to hit the public markets this week, including video streaming service Roku and specialty chemicals firm PQ Group, both valued at more than $1 billion before their IPOs.
